Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Quince Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Quince Therapeutics, Inc.

QNCX

Quince Therapeutics, Inc.

About Quince Therapeutics, Inc.

Quince Therapeutics is a late-stage biotech company developing innovative drug/device combination therapies using its proprietary AIDE platform, which encapsulates drugs into a patient’s own red blood cells for targeted, safer, and more effective treatment of rare diseases. Its lead candidate, eDSP, aims to treat neurodegenerative and autoimmune conditions like Ataxia-Telangiectasia, leveraging improved safety and biodistribution. The company focuses on clinical development, regulatory approval, and strategic partnerships in rare disease markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Quince Therapeutics, Inc.

1
1
Quince Therapeutics, Inc. Quince Therapeutics Reports $35.9 Million Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Quince Therapeutics, Inc. Quince Therapeutics Reports $83.98 Million Net Loss and Explores Strategic Alternatives

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Quince Therapeutics, Inc. Quince Therapeutics Reports 129% Increase in Operating Expenses and $13.4 Million Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Quince Therapeutics, Inc. Quince Therapeutics Reports $16M Net Loss, Decreases Operating Expenses by 63%

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Quince Therapeutics, Inc. Quince Therapeutics Reports $15M Net Loss and Increased Operating Expenses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Quince Therapeutics, Inc. Quince Therapeutics Reports $56.8 Million Net Loss for 2024, Driven by Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Quince Therapeutics, Inc. Quince Therapeutics Reports Significant Financial Decline, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments